INTEGRINS AND T CELL DEVELOPMENT AND FUNCTION
整合素与 T 细胞的发育和功能
基本信息
- 批准号:2697501
- 负责人:
- 金额:$ 23.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-09-30 至 2003-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The broad goals of this proposal are to determine the roles for integrin
receptors in the development and function of T-lymphocytes. A
combination of in vivo and in vitro approaches have been chosen. In
order to test the role of integrin receptor function in T cell
development, transgenic mice have been produced with a dominant negative
form of integrin. Specifically, we are using a construct with the
extracellular domain of the Tac antigen connected to the active integrin
beta1 cytoplasmic domain, which has been shown by us and many other
laboratories to interfere with integrin function in tissue culture
cells. The proximal lck promoter has been chosen to direct thymic
specific expression of this construct in transgenic mice, leading to an
increase in the proportion and number of thymocyte precursors,
suggesting a block in the normal differentiation of CD4- CD8- (so called
double negative cells (DN)). We now show that the Tac-beta1 construct
is acting as a transdominant inhibitor of integrin activation in the DN
population. We specifically show that there is a reduction in the
expression of an activation epitope in the integrin alpha4beta1. Our
hypothesis is that this construct has decreased the activation of a
number of integrin receptors, particularly in the DN population, whose
integrins are normally the most active in the thymus. Independently,
we will test the role of integrins in the differentiation of DN to DP
cells using antibody and peptide perturbation experiments, performed in
fetal thymic organ culture (FTOC), in which embryonic day 14 thymic
lobes are isolated and cultured for several days, during which the
thymocytes emerge from a completely DN population and differentiate into
DP. Lastly, we will test the Tac-beta1 construct as a transdominant
inhibitor of integrin activation via the T cell receptor in cultured
mouse TH2 cells. If this is successful, then using a modified CD4
promoter, we will express Tac-beta1 at high levels in the peripheral T
cells of transgenic mice to determine the role of integrin activation
in T cell function.
该提案的主要目标是确定整合素的作用,
受体在T淋巴细胞的发育和功能中的作用。 一
已经选择了体内和体外方法的组合。 在
为了检测整合素受体功能在T细胞中的作用,
发展,转基因小鼠已经产生了显性阴性
整合素的形式。具体来说,我们使用一个构造,
与活性整合素连接的Tac抗原的胞外结构域
β 1胞质结构域,这已经被我们和许多其他人所证明,
干扰组织培养中整合素功能的实验室
细胞 近端lck启动子已被选择来指导胸腺
该构建体在转基因小鼠中的特异性表达,导致
胸腺细胞前体的比例和数量增加,
提示阻断了CD 4-CD 8-(所谓的
双阴性细胞(DN))。 我们现在表明Tac-beta1构建体
在DN中作为整合素活化的反式显性抑制剂
人口 我们特别表明,有一个减少,
整合素α 4 β 1中活化表位的表达。 我们
一种假设是,这种结构降低了一种
整合素受体的数量,特别是在DN人群中,
整联蛋白通常在胸腺中最活跃。 独立地,
我们将检测整合素在DN向DP分化中的作用,
细胞使用抗体和肽扰动实验,在
胎儿胸腺器官培养(FTOC),其中胚胎第14天胸腺
分离叶并培养数天,在此期间,
胸腺细胞从完全DN群体中出现并分化为
DP. 最后,我们将测试Tac-beta1结构作为一个transdominant
通过T细胞受体的整合素活化的抑制剂
小鼠TH 2细胞 如果这是成功的,那么使用修改的CD 4
启动子,我们将在外周T细胞中高水平表达Tac-β 1。
转基因小鼠的细胞,以确定整合素活化的作用
T细胞功能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EUGENE E. MARCANTONIO其他文献
EUGENE E. MARCANTONIO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EUGENE E. MARCANTONIO', 18)}}的其他基金
Ph 2a Study of S48168 (ARM210) for CPVT 1 IND 152773 (09/11/2020)
S48168 (ARM210) CPVT 1 IND 152773 的 Ph 2a 研究 (09/11/2020)
- 批准号:
10280877 - 财政年份:2021
- 资助金额:
$ 23.9万 - 项目类别:
Ph 2a Study of S48168 (ARM210) for CPVT 1 IND 152773 (09/11/2020)
S48168 (ARM210) CPVT 1 IND 152773 的 Ph 2a 研究 (09/11/2020)
- 批准号:
10492470 - 财政年份:2021
- 资助金额:
$ 23.9万 - 项目类别:
STRUCTURE AND FUNCTION OF THE INTEGRIN ALPHA 1 BETA 1
整合素 ALPHA 1 BETA 1 的结构和功能
- 批准号:
2734661 - 财政年份:1990
- 资助金额:
$ 23.9万 - 项目类别:
STRUCTURE/FUNCTION OF THE INTEGRIN ALPHA 1 BETA 1
整合素 ALPHA 1 BETA 1 的结构/功能
- 批准号:
6386004 - 财政年份:1990
- 资助金额:
$ 23.9万 - 项目类别:
STRUCTURE AND FUNCTION OF THE INTEGRIN ALPHA1 BETA1
整合素 ALPHA1 BETA1 的结构和功能
- 批准号:
3303765 - 财政年份:1990
- 资助金额:
$ 23.9万 - 项目类别:
相似海外基金
Modulation of T lymphocyte Activation by Ã2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
RGPIN-2019-06980 - 财政年份:2022
- 资助金额:
$ 23.9万 - 项目类别:
Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10581488 - 财政年份:2022
- 资助金额:
$ 23.9万 - 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574979-2022 - 财政年份:2022
- 资助金额:
$ 23.9万 - 项目类别:
University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10332251 - 财政年份:2022
- 资助金额:
$ 23.9万 - 项目类别:
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574984-2022 - 财政年份:2022
- 资助金额:
$ 23.9万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574985-2022 - 财政年份:2022
- 资助金额:
$ 23.9万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574978-2022 - 财政年份:2022
- 资助金额:
$ 23.9万 - 项目类别:
University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
- 批准号:
444149 - 财政年份:2021
- 资助金额:
$ 23.9万 - 项目类别:
Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
- 批准号:
RGPIN-2015-05491 - 财政年份:2021
- 资助金额:
$ 23.9万 - 项目类别:
Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
- 批准号:
RGPIN-2019-06980 - 财政年份:2021
- 资助金额:
$ 23.9万 - 项目类别:
Discovery Grants Program - Individual